Renal cell carcinoma

被引：55

作者：

Garcia, Jorge A. ^{[2
]}

Cowey, C. Lance ^{[1
]}

Godley, Paul A. ^{[1
]}

机构：

[1] Univ N Carolina, Div Hematol & Oncol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

[2] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

来源：

CURRENT OPINION IN ONCOLOGY | 2009年 / 21卷 / 03期

关键词：

antiangiogenesis; mammalian target of rapamycin; multitargeted kinase inhibitor; renal cell carcinoma; von Hippel-Lindau; CARBONIC-ANHYDRASE-IX; INTERFERON-ALPHA; TARGETED THERAPY; POOLED ANALYSIS; DOUBLE-BLIND; CANCER-RISK; PHASE-II; SUNITINIB; SORAFENIB; CONSUMPTION;

D O I：

10.1097/CCO.0b013e32832a05c8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Purpose of review This review is intended to provide information on recent advancements in renal cell carcinoma (RCC) treatments as well as give insight on present-day clinical and molecularly based biomarker studies. Recent findings A review of recent literature regarding RCC epidemiology and clinical prognostic factors will be provided. Information from the latest molecularly based biomarker studies will be discussed. Finally, updates on recent additions to front-line therapy for RCC and the early clinical evidence examining the use of targeted agents sequentially or in combination will be given. Summary Changes in the treatment paradigm of advanced RCC continue to evolve with additional novel agents in the horizon. This review will provide an update of the latest concepts in the epidemiology, molecularly based biomarker development and the management of patients with advanced RCC.

引用

页码：266 / 271

页数：6

共 41 条

[1]

[Anonymous], 2008, Cancer Facts Figures 2008

[2]

Macronutrients, fatty acids, cholesterol and renal cell cancer risk [J].

Bidoli, Ettore ;

Talamini, Renato ;

Zucchetto, Antonella ;

Polesel, Jerri ;

Bosetti, Cristina ;

Negri, Eva ;

Maruzzi, Daniele ;

Montella, Maurizio ;

Franceschi, Silvia ;

La Vecchia, Carlo .

INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (11) :2586-2589

[3]

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma [J].

Choueiri, Toni K. ;

Vaziri, Susan A. J. ;

Jaeger, Erich ;

Elson, Paul ;

Wood, Laura ;

Bhalla, Ish Prasad ;

Small, Eric J. ;

Weinberg, Vivian ;

Sein, Nancy ;

Simko, Jeff ;

Golshayan, Ali-Reza ;

Sercia, Linda ;

Zhou, Ming ;

Waldman, Frederic M. ;

Rini, Brian I. ;

Bukowski, Ronald M. ;

Ganapathi, Ram .

JOURNAL OF UROLOGY, 2008, 180 (03) :860-865

[4]

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy [J].

Choueiri, Toni K. ;

Garcia, Jorge A. ;

Elson, Paul ;

Khasawneh, Mohamad ;

Usman, Saif ;

Golshayan, Ali Reza ;

Baz, Rachid C. ;

Wood, Laura ;

Rini, Brian I. ;

Bukowski, Ronald M. .

CANCER, 2007, 110 (03) :543-550

[5]

COONEY MM, 2008, J CLIN ONCOL S, V26, P3530

[6]

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].

Escudier, Bernard ;

Pluzanska, Anna ;

Koralewski, Piotr ;

Ravaud, Alain ;

Bracarda, Sergio ;

Szczylik, Cezary ;

Chevreau, Christine ;

Filipek, Marek ;

Melichar, Bohuslav ;

Bajetta, Emilio ;

Gorbunova, Vera ;

Bay, Jacques-Olivier ;

Bodrogi, Istvan ;

Jagiello-Gruszfeld, Agnieszka ;

Moore, Nicola .

LANCET, 2007, 370 (9605) :2103-2111

[7]

Phase I trial of sorafenib in combination with IFN α-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma [J].

Escudier, Bernard ;

Lassau, Nathalie ;

Angevin, Eric ;

Soria, Jean Charles ;

Chami, Linda ;

Lamuraglia, Michele ;

Zafarana, Eric ;

Landreau, Veronique ;

Schwartz, Brian ;

Brendel, Eric ;

Armand, Jean-Pierre ;

Robert, Caroline .

CLINICAL CANCER RESEARCH, 2007, 13 (06) :1801-1809

[8]

Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[9]

Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma [J].

Feldman, D. R. ;

Ginsberg, M. S. ;

Baum, M. ;

Flombaum, C. ;

Hassoun, H. ;

Velasco, S. ;

Fischer, P. ;

Ishill, N. M. ;

Ronnen, E. A. ;

Motzer, R. J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[10]

Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) [J].

Figlin, R. A. ;

Hutson, T. E. ;

Tomczak, P. ;

Michaelson, M. D. ;

Bukowski, R. M. ;

Negrier, S. ;

Huang, X. ;

Kim, S. T. ;

Chen, I. ;

Motzer, R. J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →